R. Elledge

发表

Author Correction: Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis

C. Isaacs, V. Jin, Xiaowen Zhang, 2018, Nature communications.

Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome

R. Elledge, G. Clark, G. Arpino, 2004, Breast Cancer Research.

The p53 tumor suppressor gene in breast cancer

R. Elledge, D. Allred, 2004, Breast Cancer Research and Treatment.

The role and prognostic significance of p53 gene alterations in breast cancer

S. Fuqua, R. Elledge, D. Allred, 2004, Breast Cancer Research and Treatment.

p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.

R. Elledge, D. Allred, G. Clark, 1994, Cancer research.

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

C K Osborne, R. Elledge, C. Osborne, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Adrian V. Lee, R. Schiff, C. Osborne, 2005, Journal of the National Cancer Institute.

The p53 tumor-suppressor gene in human breast cancer.

S. Fuqua, R. Elledge, D. Allred, 1994, Cancer treatment and research.

Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study.

Milton V. Marshall, R. Fisher, E. Sevick-Muraca, 2008, Radiology.

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

W. McGuire, C. Osborne, S. Fuqua, 1993, Journal of the National Cancer Institute.

Prognostic and predictive value of p53 and p21 in breast cancer

R. Elledge, D. Allred, D. Craig Allred, 2004, Breast Cancer Research and Treatment.

Primary breast cancer phenotypes associated with propensity for central nervous system metastases

S. Hilsenbeck, R. Elledge, Y. Tham, 2006, Cancer.

Survival of patients with metastatic breast carcinoma

Jenny C. Chang, R. Elledge, G. Clark, 2003, Cancer.

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

R. Gray, C. Osborne, N. Robert, 1995, Journal of the National Cancer Institute.

p53 mutation and tamoxifen resistance in breast cancer.

S. Hilsenbeck, R. Elledge, D. Allred, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

WAF1/CIP1 protein expression in human breast tumors

R. Elledge, D. Allred, S. Hilsenbeck, 1997, Breast Cancer Research and Treatment.

Prognostic significance of p53 gene alterations in node-negative breast cancer

W. McGuire, S. Fuqua, R. Elledge, 2004, Breast Cancer Research and Treatment.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Syed Mohsin, Susan G Hilsenbeck, S. Hilsenbeck, 2003, The Lancet.

K. Mitsuya, R. Elledge, T. Huang, 2020, BMC Medical Genomics.

Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.

R. Elledge, G. Clark, G. Arpino, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors.

W. McGuire, S. Fuqua, R. Elledge, 1992, Cancer research.

A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer

A. Howell, M. Dowsett, W. Gradishar, 2003, The breast journal.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

S. Hilsenbeck, R. Schiff, Jenny C. Chang, 2005, Nature Clinical Practice Oncology.

Clinical management of women with genomic BRCA1 and BRCA2 mutations*

Jenny C. Chang, R. Elledge, 2001, Breast Cancer Research and Treatment.

The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

W. McGuire, S. Fuqua, R. Elledge, 2004, Breast Cancer Research and Treatment.

2-59 High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients

R. Elledge, 2007 .

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma

C. Osborne, A. Howell, J. Robertson, 2005, Cancer.

Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers

Huai-Chin Chiang, I. Jatoi, R. Elledge, 2015, Breast cancer : basic and clinical research.

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

S. Martino, R. Elledge, G. Clark, 2000, International journal of cancer.

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

T. Julian, C. Geyer, D. Wickerham, 2015 .

Endocrine Therapy for Leptomeningeal Metastases from ER‐Positive Breast Cancer: Case Report and a Review of the Literature

R. Elledge, B. Zoghi, Behyar Zoghi, 2016, The breast journal.

The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer

S. Hilsenbeck, R. Elledge, J. Chang, 2009, Breast Cancer Research and Treatment.

A phosphotyrosine switch determines the antitumor activity of ERβ.

Huai-Chin Chiang, T. Curiel, R. Elledge, 2014, The Journal of clinical investigation.

Models for early chemoprevention trials in breast cancer.

R. Elledge, B. Kimler, C. Fabian, 1998, Hematology/oncology clinics of North America.

Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier

Huai-Chin Chiang, Sreejith J. Nair, R. Elledge, 2012, Experimental Hematology & Oncology.

Lobular neoplasia on core‐needle biopsy—Clinical significance

R. Elledge, G. Arpino, S. Mohsin, 2004, Cancer.

Rising levels of estrogen receptor in breast cancer over 2 decades

S. Hilsenbeck, R. Elledge, G. Chamness, 1994 .

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.

R. Elledge, D. V. Von Hoff, M. Villalona-Calero, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

bcl‐2 and apoptosis in lymph node positive breast carcinoma

C. Osborne, R. Elledge, D. Allred, 1998, Cancer.

Estrogen receptor, progesterone receptor, and HER‐2/neu protein in breast cancers from pregnant patients

K. Hess, R. Elledge, D. Ciocca, 1993, Cancer.

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.

S. Hilsenbeck, R. Elledge, Tao Wang, 2015, The oncologist.

Phase I II, M ulticenter, D ouble-Blind, R andomized S tudy of L etrozole, a n A romatase I nhibitor, f or A dvanced B reast Cancer V ersus M egestrol A cetate

M. Morgan, A. Buzdar, R. Elledge, 2001 .

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

C. Osborne, S. Martino, R. Elledge, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

hsp7O: Lack of Correlation with Response to Tamoxifen and Clinical Course of Disease in Estrogen Receptor-positive Metastatic Breast Cancer (A Southwest Oncology Group Study)’

S. Martino, R. Elledge, G. Clark, 2005 .

Mutation and Tamoxifen Resistance in Breast Cancer ’

S. Hilsenbeck, R. Elledge, D. Allred, 2005 .

Self-blame, Self-forgiveness, and Spirituality in Breast Cancer Survivors in a Public Sector Setting

R. Elledge, C. Barber, M. Dulay, 2010, Journal of Cancer Education.

Paget disease of a nipple graft following completion of a breast reconstruction with a nipple-sharing technique.

R. Elledge, C. Basu, J. Bullocks, 2008, Annals of plastic surgery.

Attribution of Blame, Self-forgiving Attitude and Psychological Adjustment in Women with Breast Cancer

R. Elledge, C. Osborne, M. Dulay, 2007, Journal of Behavioral Medicine.

Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).

C. Osborne, S. Martino, R. Elledge, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report.

R. Elledge, B. Teh, Y. Tham, 2006, Clinical breast cancer.

HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer

C. Osborne, S. Martino, R. Elledge, 2004, Clinical Cancer Research.

Caution concerning micrometastatic breast carcinoma in sentinel lymph nodes

R. Elledge, D. Allred, D. C. Allred, 1999, Cancer.

Premalignant and In Situ Breast Disease: Biology and Clinical Implications

R. Elledge, G. Arpino, R. Laucirica, 2005, Annals of Internal Medicine.

Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype

S. Hilsenbeck, P. O’Connell, Jenny C. Chang, 2006, Clinical Cancer Research.

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.

C. Osborne, R. Elledge, G. Clark, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis

M. Pujana, C. Isaacs, V. Jin, 2017, Nature Communications.

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

R. Schiff, R. Elledge, G. Chamness, 2010, Cancer.

Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer.

R. Elledge, D. V. Von Hoff, G. Clark, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Surgery With Improved Survival in Stage IV Breast Cancer Patients

S. Hilsenbeck, R. Elledge, S. Hilsenbeck, 2008, Annals of surgery.

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

G M Clark, C. Osborne, R. Elledge, 1994, Journal of the National Cancer Institute.

Molecular markers for predicting response to tamoxifen in breast cancer patients

R. Elledge, D. Ciocca, Richard Elledge, 2000, Endocrine.

Pharmacology, biology and clinical use of triphenylethylenes

Jenny C. Chang, R. Elledge, 2002 .

BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity

C. Isaacs, Xiaowen Zhang, Huai-Chin Chiang, 2023, Journal for ImmunoTherapy of Cancer.

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer

R. Elledge, H. Weiss, G. Arpino, 2005, Breast Cancer Research and Treatment.

Life and death by P53

R. Elledge, Wen-Hwa Lee, 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

S. Hilsenbeck, S. Fuqua, R. Elledge, 2011, Breast Cancer Research and Treatment.

Tumor characteristics and clinical outcome of elderly women with breast cancer.

R. Elledge, G. Clark, S. Diab, 2000, Journal of the National Cancer Institute.

Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas.

G M Clark, C. Osborne, R. Elledge, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

W. McGuire, R. Elledge, W L McGuire, 1992, Annual review of medicine.

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

R. Elledge, C. Osborne, G. Arpino, 2012, Breast Cancer Research and Treatment.

Prognostic factors in breast cancer.

W. McGuire, C. Osborne, D. Merkel, 1989, Hematology/oncology clinics of North America.

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

S. Martino, R. Elledge, D. Allred, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adenoid cystic carcinoma of the breast

R. Elledge, G. Clark, G. Arpino, 2002, Cancer.

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

M. Morgan, A. Buzdar, R. Elledge, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.

Syed Mohsin, Susan G Hilsenbeck, Michael T Lewis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in axillary node-negative breast cancer.

W. McGuire, R. Elledge, 1992, Cancer treatment and research.

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

Anthony Howell, A. Howell, J. Robertson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.

B. Ljung, L. Esserman, M. Cazzaniga, 2001, Journal of the National Cancer Institute.

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.

S. Hilsenbeck, Jenny C. Chang, R. Elledge, 2003, Clinical breast cancer.

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

R. Elledge, E. Romond, B. Shelton, 2013, Breast Cancer Research and Treatment.

Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers

R. Elledge, M. V. Estrada, M. M. Joly, 2018, Cell Death & Disease.

Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.

R. Zellars, R. Elledge, D. Allred, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical and Psychosocial Predictors of Delay in Seeking Medical Consultation for Breast Symptoms in Women in a Public Sector Setting

R. Elledge, M. Dulay, K. Liscum, 2006, Journal of Behavioral Medicine.

Tumor C haracteristics a nd C linical O utcome o f T ubular and M ucinous B reast C arcinomas

R. Elledge, D. Allred, G. Clark, 1999 .

Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer

C. Osborne, R. Elledge, D. Allred, 2005, Breast Cancer Research and Treatment.

Self-Forgiveness, Spirituality, and Psychological Adjustment in Women with Breast Cancer

R. Elledge, K. Liscum, L. C. Friedman, 2006, Journal of Behavioral Medicine.

Optimism, social support and psychosocial functioning among women with breast cancer

R. Elledge, M. Dulay, K. Liscum, 2006, Psycho-oncology.

The Rates of Chemotherapy-Induced Amenorrhea in Patients Treated With Adjuvant Doxorubicin and Cyclophosphamide Followed by a Taxane

R. Elledge, H. Weiss, Y. Tham, 2007, American journal of clinical oncology.

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

R. Elledge, G. Clark, P. Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

S. Hilsenbeck, Jenny C. Chang, R. Elledge, 2005, Breast Cancer Research and Treatment.

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancer

Jenny C. Chang, R. Elledge, D. Allred, 2005 .

Pathologic Changes in Breast Cancer After Anti‐Estrogen Therapy

R. Elledge, I. Yeh, T. Prihoda, 2012, The breast journal.

Second- and Third-generation Aromatase Inhibitors as First-line Endocrine Therapy in Postmenopausal Metastatic Breast Cancer Patients: A Pooled Analysis of the Randomised Trials

R. Elledge, 2007 .

Oestrogen receptors and breast cancer

R. Elledge, C. K. Osborne, R. Elledge, 1997, BMJ.

Tales from a targeted therapy.

R. Elledge, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick?

R. Elledge, 1996, Journal of the National Cancer Institute.

Rising levels of estrogen receptor in breast cancer over 2 decades.

R. Elledge, G. Chamness, S. Hilsenbeck, 1994, Cancer.

Advances in Brief Inhibition of Estrogen Receptor Action by a Naturally Occurring Variant in Human Breast Tumors 1

W. McGuire, S. Fuqua, R. Elledge, 2006 .

Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers

C. Duvall, R. Elledge, M. V. Estrada, 2018, Cell Death & Disease.

p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study

J. Michalek, R. Elledge, G. Swanson, 2016, Molecular Oncology.

EGFR expression in breast cancer: Association with biologic phenotype, prognosis, and resistance to adjuvant therapy.

R. Elledge, G. Chamness, H. Weiss, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K. Mitsuya, R. Elledge, T. Huang, 2020, BMC Medical Genomics.

Infiltrating lobular carcinoma of the breast

R. Elledge, G. Clark, G. Arpino, 2004 .

Estrogen receptor, progesterone receptor, and HER‐2/neu protein in breast cancers from pregnant patients

W. McGuire, R. Elledge, D. Ciocca, 2022 .

Phase II and Pharmacological Study of Oral Paclitaxel (Paxoral) Plus Ciclosporin in Anthracycline-Pretreated Metastatic Breast Cancer

R. Elledge, 2007 .

The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.

R. Elledge, H. Weiss, Y. Tham, 2006, The journal of supportive oncology.

Oestrogen receptors and breast cancer

C. Osborne, R. Elledge, C. K. Osborne, 1997 .

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer

Huai-Chin Chiang, T. Curiel, R. Elledge, 2016, Oncotarget.

Abstract CN04-04: Phase II trial of bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers

S. Hilsenbeck, P. Brown, N. Sneige, 2008 .

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

S. Hilsenbeck, P. O’Connell, Jenny C. Chang, 2003, The Lancet.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

R. Schiff, R. Elledge, C. Osborne, 2005, Journal of the National Cancer Institute.

BRCA1 in clinical breast cancer.

C. Osborne, R. Elledge, S. Hilsenbeck, 1998, Breast disease.

Rising levels of estrogen receptor in breast cancer over 2 decades

R. Elledge, G. Chamness, S. Hilsenbeck, 1994, Cancer.

A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue

R. Elledge, D. Allred, G. Clark, 2001 .

p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study

J. Michalek, R. Elledge, G. Swanson, 2016, Molecular oncology.